Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany

Table 2

Base-case values and ranges for quality of life estimates used in sensitivity analyses for NOACs.

Variable	Edoxaban 30 mg	Edoxaban 60 mg	Reference	Dabigatran; 110 mg bid	Dabigatran; 150 mg bid	Reference; [5]	Rivaroxaban	Reference; [5]	Apixaban	Reference; [5]
Quality of life estimates (utility)
NOAC	0.994 (0.975–1.00)	0.994 (0.975–1.00)	[12, 13, 16, 18]	0.994 (0.975–1.00)	0.994 (0.975–1.00)	[12, 13, 16, 18]	0.994 (0.975–1.00)	[12, 13, 16, 18]	0.994 (0.975–1.00)	[12, 13, 16, 18]
Warfarin	0.987 (0.953–1.00)	0.987 (0.953–1.00)	[12, 16, 18]	0.987 (0.953–1.00)	0.987 (0.953–1.00)	[12, 16, 18]	0.987 (0.953–1.00)	[12, 16, 18]	0.987 (0.953–1.00)	[12, 16, 18]
Neurological sequelae
Mild	0.87 (0.00–1.00)	0.87 (0.00–1.00)	[21]	0.87 (0.00–1.00)	0.87 (0.00–1.00)	[21]	0.87 (0.00–1.00)	[21]	0.87 (0.00–1.00)	[21]
Moderate	0.68 (0.00–1.00)	0.68 (0.00–1.00)	[21]	0.68 (0.00–1.00)	0.68 (0.00–1.00)	[21]	0.68 (0.00–1.00)	[21]	0.68 (0.00–1.00)	[21]
Serious	0.52 (0.00–1.00)	0.52 (0.00–1.00)	[21]	0.52 (0.00–1.00)	0.52 (0.00–1.00)	[21]	0.52 (0.00–1.00)	[21]	0.52 (0.00–1.00)	[21]
Recurrent event	0.12 (0.00–1.00)	0.12 (0.00–1.00)	[13]	0.12 (0.00–1.00)	0.12 (0.00–1.00)	[13]	0.12 (0.00–1.00)	[13]	0.12 (0.00–1.00)	[13]
Myocardial infarction	0.5 (0.00–1.00)	0.5 (0.00–1.00)	Assumption [12, 20]	0.5 (0.00–1.00)	0.5 (0.00–1.00)	Assumption [12, 20]	0.5 (0.00–1.00)	Assumption [12, 20]	0.5 (0.00–1.00)	Assumption [12, 20]
Hemorrhage
Major hemorrhage	0.85 (0.00–1.00)	0.85 (0.00–1.00)	Assumption [12, 19, 22]	0.85 (0.00–1.00)	0.85 (0.00–1.00)	Assumption [12, 19, 22]	0.85 (0.00–1.00)	Assumption [12, 19, 22]	0.85 (0.00–1.00)	Assumption [12, 19, 22]
Minor hemorrhage	0.95 (0.00–1.00)	0.95 (0.00–1.00)	[12, 18]	0.95 (0.00–1.00)	0.95 (0.00–1.00)	[12, 18]	0.95 (0.00–1.00)	[12, 18]	0.95 (0.00–1.00)	[12, 18]